Document Detail

Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
MedLine Citation:
PMID:  8774625     Owner:  NLM     Status:  MEDLINE    
Lipid lowering therapies were employed to prevent restenosis following elective percutaneous transluminal coronary angioplasty (PTCA). The effect of probucol was compared to that of Pravastatin in 141 coronary atherosclerosis patients. Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2). Pravastatin (10 mg/day) was administered for at least 30 days prior to PTCA (38 patients, group V-1) or less than 14 days prior to PTCA (42 patients, group V-2). In group P-1, the patient restenosis rate was 17.6% and lesion restenosis rate was 14%. These rates were significantly lower than those of group V-1, which were 44.7% and 40.4% respectively (p < 0.05). The respective values were 48.1% and 51.8% in group P-2 (p < 0.05, vs group P-1) and 35.7% and 34% (p < 0.05, vs group P-1) in group V-2. Probucol seems to work, not only by lowering cholesterol but also by its antioxidative properties when administered for a sufficient period prior to PTCA.
Y J Lee; H Daida; H Yokoi; H Miyano; J Takaya; H Sakurai; H Mokuno; H Yamaguchi
Related Documents :
24884935 - Tandem keyhole foraminotomy in the treatment of cervical radiculopathy: retrospective r...
22018185 - Glucocorticoids in rheumatoid arthritis: lessons from the utrecht study.
24953015 - Extrafine beclomethasone/formoterol in severe copd patients with history of exacerbations.
22187055 - The presence of anti-citrullinated protein antibodies (acpa) and rheumatoid factor on p...
19730105 - News in wound healing and management.
17625375 - Successful use of endoscopic argon plasma coagulation for patients with early gastric c...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Japanese heart journal     Volume:  37     ISSN:  0021-4868     ISO Abbreviation:  Jpn Heart J     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-03     Completed Date:  1996-10-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401175     Medline TA:  Jpn Heart J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  327-32     Citation Subset:  IM    
Department of Cardiology, Juntendo University, School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Anticholesteremic Agents / therapeutic use*
Coronary Artery Disease / prevention & control,  therapy*
Middle Aged
Pravastatin / therapeutic use
Probucol / therapeutic use*
Prospective Studies
Reg. No./Substance:
0/Anticholesteremic Agents; 23288-49-5/Probucol; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Significant characteristics of variant angina patients with associated syncope.
Next Document:  Assessment of left atrial pressure and volume changes during atrial systole with transesophageal pul...